1. Chronic Treg reduction results in dermal fibrosis.
Chronic Treg reduction results in dermal fibrosis. (A) αSMA-RFP mice (WT) or FoxP3DTR−/+/αSMA-RFP (FoxP3DTR−/+) mice (heterozygous for the FoxP3DTR transgene) were treated with DT every 3 days, and skin was harvested on day 28. (B) Representative histograms and flow cytometric quantification of αSMA expression on dermal fibroblasts on day 28. (C) Representative αSMA staining of dorsal skin tissue sections on day 28 after DT treatment and quantification of αSMA staining intensity. (D) Representative Masson’s trichrome staining of dorsal skin tissue sections and quantification of collagen density. (E) Representative H&E stain and quantification of dermal thickness indicated by red line on the image. (F) qRT-qPCR for fibrosis-associated genes on mRNA isolated from whole skin of WT or FoxP3DTR−/+ mice on day 28. Fold change in expression levels of profibrotic, antifibrotic, TGF-β pathway, and cytokine genes is shown. All data are representative of three independent experiments, n = 5 mice per group, per experiment. Data are mean ± SEM. Unpaired t test, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < Scale bars, 100 μm.
Lokesh A. Kalekar et al. Sci. Immunol. 2019;4:eaaw2910
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works